Suchergebnisse - "Antibodies, Monoclonal, Humanized"

PubPharm (56.201)

61

Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab

enthalten in: Liver international : official journal of the International Association for the Study of the Liver | 2024

von Rimini, M. | Stefanini, B. | Tada, T. | +75

62

Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma

enthalten in: The New England journal of medicine | 2024

von Choueiri, T. | Tomczak, P. | Park, S. | +131

63

Adjuvant Immunotherapy for Kidney Cancer - A New Strategy with New Challenges

enthalten in: The New England journal of medicine | 2024

von Voss, M. | Motzer, R.

64

Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy : the ARON-2 study

enthalten in: Cancer immunology, immunotherapy : CII | 2024

von Massari, F. | Santoni, M. | Takeshita, H. | +94

65

Soluble programmed death ligand 1 as prognostic biomarker in non-small cell lung cancer patients receiving nivolumab, pembrolizumab or atezolizumab therapy

enthalten in: Scientific reports | 2024

von Brun, S. | Hansen, T. | Wen, S. | +5

66

An economic evaluation of eptinezumab for the preventive treatment of migraine in the UK, with consideration for natural history and work productivity

enthalten in: The journal of headache and pain | 2024

von Griffin, E. | Shirley, G. | Lee, X. | +3

67

Long-term drug survival of adalimumab, infliximab, secukinumab and ustekinumab in hidradenitis suppurativa : a Danish nationwide cohort study

enthalten in: The British journal of dermatology | 2024

von Ring, H. | Thorsen, J. | Kirby, B. | +10

68

Pairing obinutuzumab with venetoclax in relapsed CLL

enthalten in: Leukemia & lymphoma | 2024

von Rogers, K. | Thompson, P.

69

Profiling lecanemab as a treatment option for Alzheimer's disease

enthalten in: Expert review of neurotherapeutics | 2024

von Schiller, E. | Silverglate, B. | Grossberg, G.

70

Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USA

enthalten in: PharmacoEconomics | 2024

von Lin, S. | Shapouri, S. | Parisé, H. | +4